Search Results for "Dutasteride Prostate Cancer"
Original Source: Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation Therapy
RATIONALE: Dutasteride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well dutasteride works in treating patients with recurrent prostate cancer that did not respond to androgen-deprivation therapy.
Matching Channels
Prostate cancer is the most common cancer in men in the UK; affecting 250,000 men. Risk factors for prostate cancer include age (average age at diagnosis is 70), a family history and a Caribbean or...
Prostate cancer is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostate ca...
Prostate Cancer Cellular Vaccine rDNA
The most common system to evaluate and describe prostate cancer currently in use is the Gleason grading system. After a biopsy, the pathologist assigns a primary grade from 1 to 5, with 5 being the...
Prostate specific membrane antigen PSMA
Prostate-specific membrane antigen (PSMA) is a transmembrane protein commonly found on the surface of late-stage and metastatic prostate cancer and a well-known imaging biomarker for staging and monit...
Matching News
Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%
The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typica...
Follow-up to REDUCE study shows low rate of prostate cancer diagnosis
The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typica...
Dutasteride delays PSA progression
The 5α-reductase inhibitor, dutasteride, delays the clinical progression of prostate cancer in patients with prostate-specific antigen levels that have failed to reduce adequately following radical t...
Prostate cancer: Third time lucky? Dutasteride for tertiary prevention of prostate cancer
Rising PSA After Prostatectomy: What to Do?
A new study finds that dutasteride delays biochemical progression of prostate cancer after radical therapy, but is that enough to recommend it? Dr. Gerald Chodak discusses the issues Medscape Urolog...
Objective To assess the role of dutasteride in preventing clinical progression of benign prostatic hyperplasia in asymptomatic men with larger prostates.Design Post hoc analysis of four year, double.....
Better Prostate Cancer Diagnosis - Image-Guided Biopsy
Magnetic resonance ultrasound fusion targeted biopsy is a better way to accurately diagnose prostate cancer, scientists from the University of California, Los Angeles, have found. Prostate cancer is t...
A Look At The Prostate Cancer Treatment Market
ByEmerging Equities:According to research firm RNCOS, the number of newly diagnosed global cancer cases is expected to reach over 17 million by 2020. The U.S. is the largest market for cancer drugs....
Matching PubMed Articles
Prostate cancer: Third time lucky? Dutasteride for tertiary prevention of prostate cancer.
Dutasteride and prostate cancer.
This overview presents new studies on prostate cancer. The effect of dutasteride and the dependency of age, risk constellation, and tumor-specific survival on prostate cancer are described. In additio...
Prostate cancer : Current and practice-relevant news from urology in 2011.
The effect of 5α reductase inhibitors in prostate cancer has been extensively investigated. The studies determined that finasteride and also dutasteride reduced the risk of prostate cancer; however,...
OBJECTIVE: The objective of this study was to assess the effect of dutasteride on serum prostate specific antigen (PSA) levels in men with serologic relapse following radical prostatectomy and/or radi...
